>

Roy Vagelos - Regeneron Pharmaceuticals Chairman of the Board

<div class='circular--portrait' style='background:#0D8ECF;color: white;font-size:4em;padding-top: 25px;;'>RE</div>
REGN -- USA Stock  

Fiscal Quarter End: March 31, 2020  

  Chairman
Dr. P. Roy Vagelos, M.D., is an Chairman of the Board of the Company. Dr. Vagelos was Chairman of the Board and Chief Executive Officer of Merck Co., Inc., a global pharmaceutical company. He joined Merck in 1975, became a director in 1984, President and Chief Executive Officer in 1985, and Chairman in 1986. Dr. Vagelos retired from all positions with Merck in 1994. Dr. Vagelos served on the board of directors of Theravance, Inc. through April 2010
Age: 88  Chairman Since 1995  Ph.D    
914 847-7000  www.regeneron.com
Vagelos is a member of the National Academy of Sciences, the National Academy of Medicine, and the American Philosophical Society. During his tenure as Chairman of the Company and previously as Chairman and Chief Executive Officer of Merck, Dr. Vagelos developed an extensive understanding of the complex business, operational, scientific, regulatory, and commercial issues facing the pharmaceutical industry.

Management Efficiency

The company has return on total asset (ROA) of 13.61 % which means that it generated profit of $13.61 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 18.87 % meaning that it created $18.87 on every $100 dollars invested by stockholders.
The company currently holds 738 M in liabilities with Debt to Equity (D/E) ratio of 7.0 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Regeneron Pharmaceuticals has Current Ratio of 3.95 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Found 9 records

CHAIRMAN Since

Joshua BogerVertex Pharmaceuticals Incorpor
2009
Michael McCallisterZoetis
2015
Yasheng YangOrigin Agritech Limited
2010
Jeffrey LeidenVertex Pharmaceuticals Incorpor
2012
Joseph PapaPerrigo Company Plc
2015
G PrasadDr Reddys Laboratories Ltd
2014
Gengchen HanOrigin Agritech Limited
2016
Marry BrlasPerrigo Company Plc
2016
Satish ReddyDr Reddys Laboratories Ltd
2014

Company Summary

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York. Regeneron Pharmaceuticals operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 8100 people.Regeneron Pharmaceuticals (REGN) is traded on BATS Exchange in USA and employs 8,100 people.

Regeneron Pharmaceuticals Leadership Team

Charles Baker, Independent DirectorView
Joseph Goldstein, Independent DirectorView
Anthony Coles, Independent DirectorView
George Sing, Independent DirectorView
Peter Powchik, Senior Vice President - Clinical DevelopmentView
Jay Markowitz, Senior Vice President - Portfolio ManagementView
Robert Terifay, Sr. VP of CommercialView
Robert Landry, CFO and Sr. VP of Fin.View
Michael Brown, Independent DirectorView
Christine Poon, Independent DirectorView
Neil Stahl, Executive VP of RandDView
Marion McCourt, Senior Vice President and Head of CommercialView
George Yancopoulos, Chief Scientific Officer and President - Regeneron Laboratories, DirectorView
Huda Zoghbi, DirectorView
Bonnie Bassler, DirectorView
Joseph LaRosa, Senior Vice President General Counsel, SecretaryView
Daniel Plew, Senior Vice President General Manager - Industrial Operations and Product SupplyView
Leonard Schleifer, President CEO, DirectorView
Alfred Gilman, Independent DirectorView
Roy Vagelos, Chairman of the BoardView
Michael Aberman, Vice President - StrategyView
Manisha Narasimhan, IR ContactView
Douglas McCorkle, Vice President Controller, Assistant TreasurerView
Marc TessierLavigne, Independent DirectorView
Christopher Fenimore, Vice President ControllerView
Arthur Ryan, Independent DirectorView

Stock Performance Indicators

Current Sentiment - REGN

Regeneron Pharmaceuticals Investor Sentiment

Majority of Macroaxis users are at this time bullish on Regeneron Pharmaceuticals. What is your perspective on investing in Regeneron Pharmaceuticals? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Currently Active Assets on Macroaxis

GM   
Purchased over 100 shares of
few hours ago
Traded for 30.71
ECA   
Purchased over 500 shares of
few hours ago
Traded for 3.54
GM   
Purchased over 100 shares of
few hours ago
Traded for 30.71
WD   
Purchased over 40 shares of
few hours ago
Traded for 66.38
DD   
Purchased over 70 shares of
few hours ago
Traded for 43.18
Additionally, take a look at Your Equity Center. Please also try Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.